News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Deals
Japan’s Astellas Pharma Inc. to Buy U.S. Agensys, Inc. for $387 Million
November 27, 2007
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
TOKYO, Nov 27 (Reuters) - Japanese drugmaker Astellas Pharma Inc (4503.T: Quote, Profile, Research) said on Tuesday it would buy U.S. biotech company Agensys Inc for $387 million to boost its antibody research and development for cancer treatments.
Twitter
LinkedIn
Facebook
Email
Print
Mergers & acquisitions
Asia
Astellas Pharma US, Inc.
MORE ON THIS TOPIC
Drug Development
Genmab drops 2 antibody assets, including another ProfoundBio ADC
May 15, 2026
·
2 min read
·
Gabrielle Masson
Funding
Degron adds $40M to series A, supporting immunology plans for molecular glue platform
May 14, 2026
·
2 min read
·
Tristan Manalac
Job Trends
Hiring outlook: job opportunities on
BioSpace
rise YOY, but layoffs affect thousands
May 14, 2026
·
3 min read
·
Angela Gabriel
Manufacturing
Bora inks $122.5M takeover of MacroGenics facility to further US expansion
May 13, 2026
·
2 min read
·
Nick Paul Taylor